Bone Metabolism in Inflammatory Bowel Diseases 2

Česká verzia

Authors: Tomáš Kupka; Pavel Svoboda; Martina Bojková; Martin Blaho; Adam Vašura ; Vladimír Hrabovský; Petr Dítě
Authors place of work: Oddělení gastroenterologie Interní klinika LF OU a FN Ostrava
Published in the journal: Vnitř Lék 2020; 66(7): 432-436
Category:

Summary

Inflammatory Bowel Disease encompasses Crohn’s Disease, which is capable of affecting the entire GI tract, although usually favors the ileocolonic and perianal areas, and Ulcerative Colitis, which is limited to the colon. The pathophysiology is not fully understood but is thought to be caused by a complex interplay among gut microbiota, dysregulation of the host’s immune system, genetic susceptibility and environmental factors. Osteopenia and osteoporosis are considered to be extraintestinal manifestations of inflammatory bowel disease. Osteoporosis is usually diagnosed by dual-energy X-ray absortiometry. Early interventions to treat active CD and preventative treatment strategies to reduce excessive bone loss might prevent long term consequences of bone loss, including fractures. The immune response in IBD includes increased production of variety of proinflammatory cytokines such as IL1β, TNFα, IL6 a IL1 from T cells and macrophages. These have both direct and indirect effects on bone turnover. Vitamin D is vital in mantenance of bone strenght, mineralisation and fracture prevention. Vitamin D’s physiological importance has also been implicated in a number of inflammatory diseases, mainly asthma, atherosclerosis and autoimmune disease.

Keywords:

bone mineral density (BDM) – inflammatory bowel disease – osteoporosis – vitamin D

Zdroje

1. Ross AC, Manson JE, Abrams SA, et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. J Clin Endocrinol Metabol 2011; 96: 53–58.

2. Wobke TK, Sorg BL, Steinhilber D. Vitamin D in inflammatory diseases. Front Physiol 2014; 5: 244.

3. Reich KM, Fedorak RN, Madsen K, et al. Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. World J Gastroenterol 2014; 20: 4934-4947.

4. Tan B, Li P, Lv H, et al. Vitamin D and BMD in Chinese IBD patients. Journal of Digestive Diseases 2014; 15: 116–123.

5. Bancil AS, Poullis A. The Role of Vitamin D in Inflammatory Bowel Disease. Healthcare (Basel) 2015; 3: 338–350.

6. Holick MF, MacLaughlin JA, Clark MB, et al. Photosynthesis of previtamin D3 in human skin and the pathologic consequences. Science 1980; 210: 203–205.

7. Holick MF. Vitamin D: a millennium prospective. J Cell Biochem 2003; 88: 296–307.

8. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005; 2: 94–111.

9. Krela- Kaźmierczak I, Szymczak A, Łykowska- Szuber L, et al. The importance of vitamin D in the pathology of bone metabolism in inflammatory bowel diseases. Arch Med Sci 2015; 11: 1028–1032.

10. Van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93–101.

11. Katz S, Weinerman S. The elderly inflammatory bowel disease patient and osteoporosis. Aging Health 2012 8: 31–42.

12. Palmer MT, Weaver CT. Linking vitamin D deficiency to inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2245–2256.

13. Horiuchi Y, Shimakura S. Mesalazine and photosensitivity. Am J Gastroenterol 1999; 94: 3386–3387.

14. Fletcher J, Cooper SC, Ghosh S, et al. The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. Nutrients 2019; 11: 1019.

15. Ulitsky A, Ananthakrishanan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. J Parenter Enteral Nutr 2011; 35: 308–316.

16. Pappa HM, Grand MJ, Gordon CM. Report on vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006; 12: 1162–1174.

17. Płudowski P, Kryśkiewicz E. Rules and standards for evaluating supplementation of the body supply of vitamin D in the light of its pleiotropic effect. Post Nauk Med 2012; 3: 265–272.

18. Cross HS, Nittke T, Kallay E. Colonic vitamin D metabolism: implications for the pathogenesis of inflammatory bowel disease and colorectal cancer. Mol Cell Endocrinol 2011; 347: 70–79.

19. Sun J. Vitamin D. and mucosal immune function. Curr Opin Gastroenterol 2010; 26: 591–595.

20. Wang T, Zhang F, Richards JB. Common genetic determinants of vitamin D insufficiency: a genome -wide association study. Lancet 2010; 376: 180–188.

21. Nagpal S. Noncalcemic actions of vitamin D receptor ligands. Endocrine Rev 2005; 26: 662–687.

22. Morrison NA, Qi JC, Takita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284–287.

23. Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene polymorphism: association with Crohn’s disease susceptibility. Gut 2000; 47: 211–214.

24. Atkins GJ, Anderson PH, Findlay DM, et al. Metabolism of vitamin D3 in human osteoblasts: evidence of autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007; 40: 1517–1528.

25. Kogawa M, Findlay DM, Anderson PH, et al. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism form optimization of bone resorption. Endocrinology 2010; 151: 4613–4625.

26. Ryżko J Calcium and phosphate metabolism in gastrointestinal physiology and pathology. Pediatr Wspolcz Gastroenterol Hepatol Żyw Dziecka 2001; 3: 111–117.

27. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med 2010; 88: 441–450.

28. Cantorna TM, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80: (Suppl.): 1717–1720.

29. Mahon BD, Wittke A, Weaver V, et al. The targets of vitamin D depend of the differentiation and activation status of CD4 positive cells. J Cell Biochem 1989; 89: 922–932.

30. Schwalfenberg GK. Solar radiation and vitamin D: mitigating environmental factors in autoimmune disease. J Environ Public Health 2012; 2012: 619381.

31. Boonstra A, Barrat FJ, Crain C, et al. 1alpha, 25-dihydroxyvitamin D3 has effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974–4980.

32. Szczawińska- Popłonyk A, Bręborowicz A. Vitamin D impact on immune functions: implications for preventive strategy or allergic disease? Postep Derm Alergol 2012; 3: 176–181.

33. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical research. Gut 2008; 57: 684–694.